Top View
- The State of Research in Dmd
- Injections: Drugs EH Policy
- Long-Term Safety and Efficacy of Golodirsen in Male Patients With
- Amondys 45™ (Casimersen)
- And Golodirsen-Treated Duchenne Muscular Dystrophy Patients
- Injections, Vaccines, and Other Physician- Administered Drugs
- Drug Information Center Highlights of FDA Activities – 8/1/2020
- Prior Authorization — Select
- Medications for Duchenne Muscular Dystrophy SERVICE: Casimersen
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahr 2020
- Nonpayable Drug List
- Optumrx Drug Pipeline Insights Report
- Bureau for Medical Services
- Increased Dystrophin Production with Golodirsen in Patients with Duchenne Muscular Dystrophy
- Medical Coverage Policy Retirement Notice Medical Coverage Policies Retired, Or for Which Review Has Transitioned to Interqual®, Evicore®, Or Other Resources
- Pharmacy Investigative List Effective: August 26, 2021
- Prior Authorization List* for Blue Shield and FEP Members Effective July 1, 2021
- New Drugs & Biologics
- Services and Medicare Part B Drugs These Services May Or May Not Be Covered by Your Healthpartners Plan
- Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value
- Novel Treatments for Orphan Diseases: a Promising Future September 20Th, 2019
- Overview of Gene Therapy in Spinal Muscular Atrophy and Duchenne
- 1 Basil Darras, MD (Chief of the Division of Clinical Neurology
- (Golodirsen), Exondys 51 (Eteplirsen), Viltepso (Viltolarsen) MB2118
- GOLODIRSEN) Policy Number: CSLA2020D0086A Effective Date: TBD
- 213026Orig1s000
- Therapeutic Strategies for Duchenne Muscular Dystrophy: an Update
- Authorization Requirements Medicare -Feb 15
- Prior Authorization and Investigational Services List
- Therapeutic Update on Neuromuscular Disorders SMA and DMD Conference Highlights from 2018 Disclaimer
- Authorizations for Medical Drugs
- CCS NL 02-0321 Treatment Of
- Services and Medicare Part B Drugs These Services May Or May Not Be Covered by Your Healthpartners Plan
- Antisense Oligonucleotides: an Emerging Area in Drug Discovery and Development
- Proteogenomic Landscape of Uterine Leiomyomas from Hereditary Leiomyomatosis and Renal Cell Cancer Patients Nicholas W
- Procedures, Programs, and Drugs That Require Precertification
- Medical Drug Prior Authorization List/External Posting Effective August 2021 Page 1 Last Updated 8/4/2021
- VYONDYS 53 (Golodirsen) Injection, for Intravenous Use • Hypersensitivity Reactions: Hypersensitivity Reactions, Including Rash, Initial U.S
- Duchenne Muscular Dystrophy Genetic Therapies Approved By: UM Pharmacy Subcommittee
- Pipeline Report Report
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- First Quarter, 2020 Coding Cycle for Drug and Biological Products
- Pharmacy Medical Services Prior-Authorization List
- Precision Genetic Medicine for Rare Neuromuscular Diseases
- RNA-Targeted Therapies and High-Throughput Screening Methods
- Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value
- ACTA MYOLOGICA (Myopathies, Cardiomyopathies and Neuromyopathies)
- Labeling: • Hypersensitivity Reactions [See Warnings and Precautions (5.1)]
- Prior Authorization List for the Medicaid (GHP Family)
- Riv ACTA Myo 1 2018.Pdf
- Providers | Gene Based Therapy for Duchenne Muscular Dystrophy Policy